The FDA has approved a drug that could extend the survival of those with metastatic pancreatic cancer. A late-stage clinical trial with 500 patients showed that the median overall survival nearly doubled to more than 13 months versus a median survival of about 6.7 months for those being treated with standard chemotherapy. #fda #cancer #health #news #abcnews